POST TEST Update in Hematologic Cancers January 26, 2018

Question Title

* 1. Medical Specialty:

Hematology Oncology

Medical Oncology

Radiation Oncology

Primary Care/Family Medicine

Oncology Nurse

Oncology Fellow

Radiology

Pathology

Social Worker

Other (please specify)

Question Title

* 2. Practice Setting:

Academic

Hospital-based

Clinic

Group

Laboratory

Private Practice

Researcher

Ambulatory

Long-term care

Other (please specify)

Question Title

* 3. Academic Degree

PhD

MD, PhD

APRN

BSN

CCRN

CRNP

PharmD

MSN

CRNP

PA-C

Other (please specify)

Question Title

* 4. 56 y/o man with Stage 3B DLCL s/p R-CHOP with PR, after RICE x 4 with PR and high dose BEAM and ASCT with CR but relapsed 2 years later. All the following are true concerning CD-19 directed therapies in Relapsed/Refractory Lymphoma except:

CD-19 CAR can induce potent and durable responses for pts with relapsed/refractory NHL

CD-19 CAR is frequently associated with significant CRS that responded well to anti–IL-6 treatment

CD-19 CAR is indicated for initial therapy for high risk NHL

D. Robust in vivo expansion can be maintained with the possibility of sustained long-term disease control

Question Title

* 5. 65 y/o woman with AML with INV 16 cytogenetics. Which statements concerning the treatment of AML induction therapy are true?

FLT-3 ITD positive AML benefits from addition of FLT-3 oral inhibitors into induction therapy

AML with good risk cytogenetics (INV16, 8;21) benefits from the addition of gentuzumab-ozogamicin (GO) to 3+7 induction therapy.

Liposomal daunorubicin + Cytarabine is superior to 3 + 7 induction for older patients with therapy-related AML.

All of the above

Question Title

* 6. 65 y/o man with myeloma manifested by lytic bone lesions has VGPR to VRD and undergoes high dose melphalan and ASCT consolidation and enters CR but MRD positive by flow cytometry. The following are true about maintenance therapy for myeloma after ASCT

ASCT followed by lenaldiomide maintenance remains the standard of care for ASCT eligible patients with early myeloma

Daratumumab is a low toxicity, effective maintenance therapy after ASCT for myeloma

Due to the risk of second primary malignancies, lenalidomide maintenance should be used very sparingly if at all after ASCT for myeloma

Bortezomib in combination with lenalidomide is superior to lenalidomide alone as maintenance therapy for standard risk myeloma